Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide

Next Previous
Trial Profile

A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trabectedin (Primary) ; Dacarbazine
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SAR3007
  • Sponsors Janssen Research & Development

Most Recent Events

  • 22 Apr 2021 According to Specialised Therapeutics Asia media release, the Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen, based on results from this study.
  • 10 Sep 2019 Results assessing the safety and efficacy of Trabectedin when administered in the inpatient versus outpatient setting (n=378), published in the Cancer
  • 07 Jun 2019 Subgroup analysis results were published in the Cancer.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top